Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01702012 · ClinicalTrials.gov registry record · NA
Almased Multi-Center Diabetes Intervention Trial
A NA study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 240
- Enrollment target
NCT01702012: Completed NA study, sponsored by Wake Forest University Health Sciences.
NCT01702012 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 240 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01702012, a NA study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
Study Summary
A 12 month multi-center randomization controlled study. Participants will be randomized to either a lifestyle education program or a meal replacement regimen with Almased, after an initial examination of eligibility criteria. Primary outcome-HbA1c
Interventions
- DIETARY_SUPPLEMENT Almased Meal Replacement Powder
- BEHAVIORAL Group-Based Lifestyle Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-05 |
| Phase | NA |
What the finished NCT01702012 record still lists
NCT01702012 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Almased Meal Replacement Powder is the first listed.
NCT01702012 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01702012 about?
NCT01702012 is a clinical study titled "Almased Multi-Center Diabetes Intervention Trial". A 12 month multi-center randomization controlled study. Participants will be randomized to either a lifestyle education program or a meal replacement regimen with Almased, after an initial examination of eligibility criteria. Primary outcome-HbA1c
What is the current status of trial NCT01702012?
This trial is currently completed. It is a NA study. The enrollment target is 240 participants. The study started on 2013-01. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01702012?
The interventions under investigation include: Almased Meal Replacement Powder (DIETARY_SUPPLEMENT), Group-Based Lifestyle Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT01702012?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01702012's enrollment target sits among peer trials
240 440th of 2000 higher than 1,542 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia